Microsoft’s latest quantum computing update is more than another chip announcement. With Majorana 2, the company is trying to show that the race toward practical quantum computing may move faster when advanced hardware meets agentic AI.

Majorana 2 is built around topological qubits, a type of qubit designed to be more stable and less vulnerable to errors than many conventional quantum systems. Stability matters because quantum computers are extremely sensitive to noise, temperature changes, and tiny environmental disturbances. Even small errors can make calculations unreliable. Microsoft says Majorana 2 improves qubit reliability significantly compared with its earlier work, which could bring the industry closer to scalable quantum machines.

A major part of this progress comes from Microsoft Discovery, the company’s agentic AI platform for scientific research. Instead of relying only on slow trial-and-error lab work, Microsoft used AI agents to help identify better materials, optimize experiments, analyze results, and support faster decision-making. This is important because quantum computing is not just a software challenge. It depends heavily on breakthroughs in materials science, chip design, and advanced manufacturing.

Want deeper insights into the rapidly evolving quantum processors market? Request a customized quote today.

The company’s approach also points to a larger shift in deep technology: AI is no longer just helping people write code or summarize data. It is starting to act as a research partner. In fields such as quantum computing, drug discovery, energy storage, and semiconductor development, agentic AI could shorten development timelines by testing ideas faster and helping researchers focus on the most promising paths.

For businesses and governments, the implications are significant. A reliable, fault-tolerant quantum computer could one day transform complex simulations, cybersecurity, logistics, climate modeling, financial risk analysis, and molecular research. That said, quantum computing still has a long road ahead. Microsoft’s claims will need continued scientific validation, and the industry must still solve major challenges around scaling, error correction, and commercial deployment.

Explore market forecasts, technology trends, and competitive analysis. Download the complete Table of Contents.

Even so, Majorana 2 is an important signal. It suggests that the future of quantum computing may not depend on hardware innovation alone. The next major leap could come from the combination of quantum chips, advanced materials, and AI systems that help scientists discover faster.

Request an updated version on Quantum Processor Market

In a historic first for perioperative oncology, Johnson & Johnson's apalutamide slashed metastasis risk by 20% and achieved near-complete cancer clearance nine times more often than standard hormone therapy alone.

Johnson & Johnson has made one of the most closely watched oncology announcements from ASCO 2026, reporting that its prostate cancer therapy ERLEADA, also known as apalutamide, significantly reduced the risk of metastasis or death when used before and after surgery. The results come from the Phase 3 PROTEUS study, a large randomized trial involving patients with high-risk localized or locally advanced prostate cancer who were eligible for radical prostatectomy. For decades, surgery has remained a core treatment option for these patients, but recurrence after surgery has continued to be a major clinical challenge. Johnson & Johnson’s new data suggest that adding systemic therapy earlier may help change that treatment pathway.

In the PROTEUS study, patients received ERLEADA plus androgen deprivation therapy for six months before surgery and six months after surgery. The trial met both of its primary endpoints: pathologic complete response or minimal residual disease at surgery, and metastasis-free survival. Patients treated with ERLEADA plus hormone therapy were nine times more likely to have little to no cancer remaining at the time of surgery, with a response rate of 8.9% compared with 1.0% for hormone therapy alone. The combination also lowered the risk of metastasis or death by 20%, a meaningful result for a patient group at high risk of disease recurrence and progression.

Explore BIS Research’s Hormone Sensitive Advanced Prostate Cancer Market report for deeper treatment-market insights.

The findings are important because high-risk localized prostate cancer can appear treatable with surgery, yet microscopic disease may remain and later lead to relapse. Johnson & Johnson reported that patients receiving the ERLEADA-based regimen went more than six years before needing subsequent therapy, compared with about three and a half years for those receiving hormone therapy alone. The study also showed a 29% reduction in the risk of disease recurrence or death and improvement in time to distant metastasis. These results position ERLEADA as a potential perioperative treatment option that could support surgery rather than replace it.

For broader disease-progression analysis, see BIS Research’s Metastatic Castration-Sensitive Prostate Cancer Market report.

The data were selected to open the plenary session at the 2026 American Society of Clinical Oncology Annual Meeting and were published simultaneously in The New England Journal of Medicine, highlighting their clinical relevance. However, Johnson & Johnson has clarified that ERLEADA plus hormone therapy is not yet approved by regulators for this earlier prostate cancer setting. Safety findings were generally consistent with previous ERLEADA studies, though higher rates of grade 3 or 4 adverse events and treatment discontinuations were reported in the ERLEADA group. Even with that caution, the PROTEUS results mark a significant development in prostate cancer care and could push oncologists toward treating aggressive disease earlier, before it spreads.

Want to know more about Prostate Cancer Testing Market.

Download the complete TOC

Request Sample Report

Explore our LinkedIn Newsletter on ASCO 2026 and the next chapter of patient-centered oncology care in this article: Read more here

IBM has announced one of the most ambitious quantum computing investments to date, committing more than $10 billion over the next five years to accelerate the development of a large-scale, fault-tolerant quantum computer by 2029.

The move signals IBM’s intent to remain at the front of the global quantum computing race, where technology leaders are working to solve one of the industry’s biggest challenges: building machines that can perform complex calculations reliably and without errors. Unlike today’s experimental quantum systems, a fault-tolerant quantum computer would be designed to correct errors during computation, making it far more useful for real-world scientific and industrial applications.

See what IBM’s quantum roadmap means for processor innovation

According to the company’s filing with the U.S. Securities and Exchange Commission, IBM’s investment will support research and development, capital expenditure, manufacturing scale-up, ecosystem partnerships, and potential acquisitions. This broad allocation shows that IBM is not treating quantum computing as a narrow research project, but as a long-term technology platform requiring hardware, software, supply chain, and commercial ecosystem development. The company has already deployed more than 90 quantum systems, which it says is more than all other industry players combined. IBM also claims that more than 325 organizations, including Fortune 500 companies, startups, universities, and government agencies, are using its quantum systems to explore challenges in chemistry, biology, materials science, and other advanced fields.

Explore how quantum computing is moving from research to real-world impact

The announcement also arrives at a time when quantum computing has become a strategic priority for governments and corporations. Reuters reported that the U.S. administration recently moved to take equity stakes worth $2 billion across nine quantum computing companies as part of an effort to strengthen national leadership in the sector and counter China’s technological progress. IBM is expected to receive half of that funding for Anderon, a new venture intended to become the first dedicated quantum chip manufacturing facility in the United States. This reflects a wider shift in which quantum technology is increasingly viewed not only as a business opportunity, but also as a matter of national competitiveness, defense readiness, and long-term strategic advantage.

Understand why quantum technology is becoming a strategic defense priority

For businesses, researchers, and investors, IBM’s $10 billion quantum computing plan could mark a turning point. If the company delivers a fault-tolerant quantum computer by 2029, it could unlock breakthroughs in drug discovery, advanced materials, logistics, climate modeling, cybersecurity, and artificial intelligence. The goal remains technically difficult, and commercial impact will depend on whether useful applications can scale alongside the hardware. At the same time, faster progress in quantum computing will increase the urgency for quantum-safe cybersecurity, as enterprises and governments prepare for a future where traditional encryption may no longer be enough.

Prepare for the cybersecurity shift triggered by quantum breakthroughs

The U.S. Department of Commerce has made one of its most significant moves yet in the global quantum technology race, signing letters of intent with nine companies for $2.013 billion in proposed federal incentives under the CHIPS and Science Act. The funding is designed to accelerate U.S. leadership in utility-scale, fault-tolerant quantum computing and strengthen the country’s domestic quantum manufacturing base.

The companies named in the announcement are IBM, GlobalFoundries, Atom Computing, Diraq, D-Wave, Infleqtion, PsiQuantum, Quantinuum and Rigetti. The funding covers two major tracks: quantum foundry infrastructure and quantum computing technology development. IBM and GlobalFoundries are expected to support domestic quantum manufacturing capacity, while the other seven companies will work across neutral atom, silicon-spin, superconducting, photonic and trapped-ion quantum computing technologies.

Explore Global Quantum Processors Market report to understand the technologies and companies shaping the next phase of quantum computing.

The largest proposed incentive is for IBM, which is expected to receive $1 billion to establish a new quantum foundry subsidiary focused on quantum-grade superconducting wafers. GlobalFoundries is expected to receive $375 million to build a secure domestic quantum foundry supporting multiple quantum architectures, including superconducting, trapped ion, photonic, topological and silicon spin systems.

The remaining awards reflect the diversity of the quantum computing race. Atom Computing and Infleqtion are focused on neutral-atom systems. Diraq is working on silicon spin quantum computing. D-Wave and Rigetti are advancing superconducting architectures. PsiQuantum is focused on photonic quantum computing, while Quantinuum is addressing trapped-ion scaling challenges.

What makes this announcement strategically important is that quantum computing is no longer being treated only as a laboratory breakthrough. The Department of Commerce explicitly connects quantum leadership with national security, technological resilience and long-term strategic leadership. Quantum systems could eventually influence defense communications, encryption, sensing, logistics, simulation and intelligence applications.

Explore Quantum Warfare Market report to examine how quantum technologies are reshaping defense, security and future warfare.

The announcement also signals a shift in how governments are approaching critical technologies. Instead of simply funding research, the U.S. is backing the industrial infrastructure needed to manufacture, scale and commercialize quantum systems. That includes foundries, wafers, packaging, cryogenic integration, control systems and advanced quantum architectures.

For the global technology industry, the message is clear: quantum computing is moving from experimental promise to strategic infrastructure. The race is no longer only about who builds the best qubit. It is about who controls the manufacturing base, supply chain, talent ecosystem and national security applications that will define the next era of computing.